Physician profile
John Kayal
NPI 1366409880
$26,907.79
in general payments reported to CMS, 2019-2025
58 companies · $3,759 in 2025
The $3,759 reported for 2025 was more than what 94% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,650 · 2020: $2,777 · 2021: $4,129 · 2022: $3,366 · 2023: $2,833 · 2024: $5,394 · 2025: $3,759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,982 · Consulting Fee: $1,738 · Education: $170 · Travel and Lodging: $96.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,981.53 |
| Consulting Fee | $1,737.50 |
| Education | $170.34 |
| Travel and Lodging | $96.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $4,919.79 | 2019-2025 | Xeomin |
| Janssen Biotech, INC. | $3,101.69 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $3,026.63 | 2019-2025 | |
| Genzyme Corporation | $2,325.48 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,946.13 | 2019-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $1,637.73 | 2019-2025 | |
| Lilly USA, LLC | $1,252.21 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Ucb, INC. | $993.32 | 2019-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $768.90 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $597.34 | 2019-2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $587.06 | 2019-2025 | Winlevi, Absorica Ld |
| Pfizer INC. | $572.71 | 2019-2025 | |
| Leo Pharma INC. | $550.72 | 2019-2025 | Adbry |
| Amgen INC. | $497.10 | 2019-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $437.32 | 2019-2023 | Targretin, Siliq |
Show all 57 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kayal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.